Oregon's psilocybin program was built to pay for itself through fees, and that model is breaking. With a $3.5 million shortfall and a proposal to double already-steep licensing costs, CPP argues the real fix is treating psilocybin therapy as a cost-saving health investment, not a luxury tax.

We’re building the case that psilocybin therapy stands to deliver better outcomes, at a lower long-term cost, than many of the existing mental health programs and treatments states are spending tens of billions of dollars on.

Oregon Health & Science University has been awarded a $3.3 million grant from the National Institute on Drug Abuse to study outcomes from legal, state-regulated psilocybin services in real-world community settings.

Over the coming months, we will be sharing a short series on Oregon’s lessons, national trends, and how states can build the first wave of affordable, state-funded access programs that meet people where they are.